Headaches in Young People and adults

26th October 2012 by Louise Hudman

This is a monster of a guideline from NICE, which is only aimed at people over the age of 12. This email contains the summary, but if you want to read more, then use the link at the bottom.

My main feeling about this guideline, having trawled though the 360 pages of evidence, is that it is more a summary of what we currently know, than a guideline. They exclude commonly used treatments like amitriptyline and pizotifen from the guideline, not because there is evidence that they are ineffective, but because the studies just haven’t been done yet. A lot of the evidence that is available, is of poor quality and is often contradictory.

From my personal point of view, this guideline will not be changing my practice much.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"I have been working with NASGP as the main source of income since graduating. I can't recommend them more highly for newly-graduated GPs. They helped me with setting my terms and conditions and they even arranged a tutorial session about EMIS, as the system was new to me.

LocumDeck is a great help when it comes to organising sessions, pension forms and invoices for tax purposes.

NASGP was particularly supportive during the Covid-19 period. It recognised the effect it had on locum work, temporarily waived the already small fee on sessions and were keen on getting the members together in regular video meetings.

I'm a satisfied member of NASGP. "

Dr Nazar Ahmed

Dr Nazar Ahmed

See the full list of features within our NASGP membership plans

Membership